PTC Inc. logo

PTC Inc. (PTC)

Market Closed
20 Jul, 20:00
NASDAQ (NGS) NASDAQ (NGS)
$
124. 83
+0.46
+0.3699%
After Hours
$
130. 45
+5.62 +4.5021%
14.15B Market Cap
83.45 P/E Ratio
- Div Yield
1.31M Volume
4.29 Eps
$ 124.37
Previous Close
Add Transaction
Day Range
122.78 126.19
Year Range
108.5 219.69
Want to track PTC and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Why PTC Inc. (PTC) is a Top Growth Stock for the Long-Term

Why PTC Inc. (PTC) is a Top Growth Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks | 9 months ago
PTC Inc. (PTC) Inc. Presents At Citi's 2025 Global Technology, Media And Telecommunications Conference Transcript

PTC Inc. (PTC) Inc. Presents At Citi's 2025 Global Technology, Media And Telecommunications Conference Transcript

PTC Inc. (NASDAQ:PTC ) Inc. Citi's 2025 Global Technology, Media and Telecommunications Conference September 4, 2025 12:50 PM EDT Company Participants Neil Barua - President, CEO & Director Kristian Talvitie - Executive VP & CFO Conference Call Participants Tyler Radke - Citigroup Inc., Research Division Presentation Tyler Radke VP & Senior Analyst Good afternoon everyone. Tyler Radke here.

Seekingalpha | 10 months ago
Here is Why Growth Investors Should Buy PTC Inc. (PTC) Now

Here is Why Growth Investors Should Buy PTC Inc. (PTC) Now

PTC Inc. (PTC) possesses solid growth attributes, which could help it handily outperform the market.

Zacks | 11 months ago
PTC Therapeutics: HD Treatment Advancement Continues With Q4 2025 Catalyst

PTC Therapeutics: HD Treatment Advancement Continues With Q4 2025 Catalyst

Company is positioned for growth with SEPHIENCE, approved for PKU in the US and Europe, and pending decisions in Japan and Brazil. Votoplam (PTC518) for Huntington's Disease shows promising phase 2 results; a key FDA meeting in Q4 2025 could enable Accelerated Approval and set a phase 3 trial design. Strong partnership with Novartis provides financial strength and development support for votoplam for treatment of HD patients, with up to $1.9 billion in milestone payments possible.

Seekingalpha | 11 months ago
Best Growth Stocks to Buy for August 18th

Best Growth Stocks to Buy for August 18th

ZWS, SHG and PTC made it to the Zacks Rank #1 (Strong Buy) growth stocks list on August 18, 2025.

Zacks | 11 months ago
PTC Inc. (PTC) Upgraded to Strong Buy: Here's Why

PTC Inc. (PTC) Upgraded to Strong Buy: Here's Why

PTC Inc. (PTC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks | 11 months ago
Looking for a Growth Stock? 3 Reasons Why PTC Inc. (PTC) is a Solid Choice

Looking for a Growth Stock? 3 Reasons Why PTC Inc. (PTC) is a Solid Choice

PTC Inc. (PTC) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Zacks | 11 months ago
Can PTC Inc. (PTC) Run Higher on Rising Earnings Estimates?

Can PTC Inc. (PTC) Run Higher on Rising Earnings Estimates?

PTC Inc. (PTC) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Zacks | 11 months ago
Here's Why PTC Inc. (PTC) is a Strong Growth Stock

Here's Why PTC Inc. (PTC) is a Strong Growth Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks | 11 months ago
PTC Inc. (PTC) Q3 2025 Earnings Call Transcript

PTC Inc. (PTC) Q3 2025 Earnings Call Transcript

PTC Inc. (NASDAQ:PTC ) Q3 2025 Earnings Conference Call July 30, 2025 5:00 PM ET Company Participants Kristian P. Talvitie - Executive VP & CFO Matthew Shimao - Senior Vice President of Investor Relations Neil Barua - President, CEO & Director Robert Dahdah - Executive VP & Chief Revenue Officer Conference Call Participants Adam Charles Borg - Stifel, Nicolaus & Company, Incorporated, Research Division Andrew Burris Obin - BofA Securities, Research Division Blair Harold Abernethy - Rosenblatt Securities Inc., Research Division Hoi-Fung Wong - Oppenheimer & Co. Inc., Research Division Jason Vincent Celino - KeyBanc Capital Markets Inc., Research Division Jay Vleeschhouwer - Griffin Securities, Inc., Research Division Joseph D.

Seekingalpha | 11 months ago
PTC Inc. (PTC) Reports Q3 Earnings: What Key Metrics Have to Say

PTC Inc. (PTC) Reports Q3 Earnings: What Key Metrics Have to Say

The headline numbers for PTC Inc. (PTC) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks | 11 months ago
PTC Inc. (PTC) Beats Q3 Earnings and Revenue Estimates

PTC Inc. (PTC) Beats Q3 Earnings and Revenue Estimates

PTC Inc. (PTC) came out with quarterly earnings of $1.64 per share, beating the Zacks Consensus Estimate of $1.22 per share. This compares to earnings of $0.98 per share a year ago.

Zacks | 11 months ago
Loading...
Load More